Endostar (recombinant human endostatin) / Simcere - LARVOL DELTA

Safety,efficacy and mechanisms of envolimab and S-1 systemic therapy combined with intraperitoneal endostar in the treatment of gastric/gastric-oesophageal junction adenocarcinoma with malignant ascites in elderly patients over 70 years. (ChiCTR) - P=N/A | N=30 | Recruiting | Sponsor: Beijing Hospital; Beijing Hospital

New trial • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology

Endostar combined with docetaxel or cisplatin in the management of malignant ascites through hyperthermic intraperitoneal chemotherapy: A retrospective cohort study. (PubMed, Oncol Lett) - "However, it is worth noting that the incidence of nephrotoxicity was higher in the cisplatin treatment group compared with that in the docetaxel treatment group. Therefore, clinicians should be cautious about nephrotoxicity when administering cisplatin in high-risk patients with PM."

Journal • Retrospective data • Oncology • Renal Disease

Endostar overcomes Osimertinib-resistance mediated EGFR-activation mutation, T790M and cis-C797S triple mutations via enhancing the binding of Osimertinib to EGFR protein. (PubMed, Life Sci) - "This work demonstrated for the first time that Endostar enhanced the antitumor efficacy of Osimertinib, offering a potential therapeutic approach for patients harboring triple mutations."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Successful treatment of lung squamous cell carcinoma with envafolimab, a PD-L1 inhibitor combined with chemotherapy: a case report. (PubMed, Transl Cancer Res) - "Initial immunohistochemistry revealed a tumor proportion score for PD-L1 ≥1%, prompting the following standard first-line therapy as per the guidelines: three cycles of albumin-bound paclitaxel [470 mg, day (d)1], carboplatin (568 mg, d1), and pembrolizumab (200 mg, d1)...Subsequently, second-line therapy comprising two cycles of gemcitabine (1.6 g, d1; 1.4 g, d8), cisplatin (40 mg, d1-3), endostar (30 mg, d1-4), and subcutaneous envafolimab (200 mg, d1) was initiated...It suggests that envafolimab warrants consideration as a viable treatment option in this setting, particularly following the failure of PD-1 inhibitors. Further larger clinical trials need to be conducted to confirm these findings and define its optimal role in the NSCLC treatment sequence."

Journal • Hepatocellular Cancer • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions (clinicaltrials.gov) - P3 | N=290 | Active, not recruiting | Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Oct 2023 ➔ Jun 2026 | Trial primary completion date: Jun 2022 ➔ Feb 2025

Enrollment closed • Trial completion date • Trial primary completion date • Respiratory Diseases

IACE-OS: Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma (clinicaltrials.gov) - P1/2 | N=10 | Completed | Sponsor: Shanghai 6th People's Hospital | Recruiting ➔ Completed | Trial completion date: Oct 2025 ➔ Jul 2025 | Trial primary completion date: Sep 2025 ➔ Apr 2025

Trial completion • Trial completion date • Trial primary completion date • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Case Report: Tail-of-the-curve advantage from immune checkpoint inhibitor-anti-VEGF combination therapy: extended survival in a patient with metastatic lung adenocarcinoma. (PubMed, Front Med (Lausanne)) - "Against this backdrop, we describe the clinical course of a patient with invasive adenocarcinoma of the left upper lobe who underwent surgical resection followed by adjuvant pemetrexed-cisplatin chemotherapy. Two years later, an isolated perihilar recurrence was treated with radical radiotherapy in combination with recombinant human endostatin (Endostar) as a radiosensitizer, after which the patient received four further cycles of the original chemotherapy regimen and subsequently transitioned to pemetrexed maintenance. Thirteen months into maintenance therapy, brain metastases were detected; at this juncture, the patient received whole-brain radiotherapy together with combined sintilimab and Endostar therapy. Although systemic treatment was discontinued after 18 months, the patient maintained disease control for an additional 36 months, consistent with a pronounced tail-of-the-curve effect. This case raises the possibility of integrating ICIs, anti-angiogenic therapy,..."

Checkpoint inhibition • Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Efficacy of chemotherapy plus recombinant human endostatin ± immunotherapy in TKI-resistant NSCLC patients (ESMO-IO 2025) - "P-values from Fisher's exact test for categorical variables.Conclusions Adding ICIs to chemotherapy plus Endostar® significantly enhanced rapid and robust disease control in TKI-resistant NSCLC patients, with excellent safety profiles. These findings support the clinical development of this triple combination strategy for TKI-resistant NSCLC."

Clinical • IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

SIMCERE PHARMA's ENZESHU and ENDOSTAR Included in China's NRDL (iis.aastocks.com)

Platinum resistant • Reimbursement • Fallopian Tube Cancer • Non Small Cell Lung Cancer • Ovarian Cancer • Peritoneal Cancer

Effects of Three Types of Movements of Nickel-Titanium Instruments on Root Canal Preparation: Analysis by Using Cone-Beam Computed Tomography. (PubMed, Materials (Basel)) - "Endostar E3 Azure files significantly reduce the thickness of the root wall along its entire length, which may indicate the effective removal of infected tissue. The use of OTR movement did not affect the analyzed parameters negatively, and it is a safe option which combines the advantageous features of rotary and reciprocal movements."

Journal • POLD1

Efficacy of a personalized combination regimen combining induction chemotherapy, immunotherapy, radiotherapy, and targeted therapy for locally advanced synchronous multiple primary lung cancer: a case report. (PubMed, J Med Case Rep) - "Clinical practice should adopt a multidisciplinary treatment-based approach, integrating clinical information, imaging data, histopathological features, and molecular characteristics to formulate individualized clinical management strategies and treatment plans. Such personalized therapeutic approaches are essential to improving long-term survival rates and quality of life in patients with synchronous multifocal lung cancer."

Journal • Lung Cancer • Oncology • Solid Tumor

Efficacy of Endostar plus concurrent chemoradiotherapy in locally advanced cervical cancer: a multicenter, phase II randomized trial. (PubMed, Ther Adv Med Oncol) - P2 | "A total of 120 patients were randomly allocated (1:1) to receive either CCRT alone (definitive radiotherapy plus cisplatin 40 mg/m2 every week for 4-5 cycles) or CCRT plus Endostar, Endostar at a dose of 7.5 mg/m2/day, from 5 days before CCRT for 10 consecutive days every 15 days for four cycles)...Although the 5-year DMFS results are encouraging, validation in a larger phase III study and longer follow-up are warranted before considering this regimen as a new standard treatment modality for LACC. This trial was registered at ClinicalTrials.gov (NCT03086681, registered 22 March 2017, https://clinicaltrials.gov/study/NCT03086681."

Journal • P2 data • Cardiovascular • Cervical Cancer • Gynecology • Hypertension • Obstetrics • Oncology • Solid Tumor • Squamous Cell Carcinoma • Women's Health

Impact of Different Nickel-titanium Instruments on Apical Micro-cracks Formation and Residual Amount of Root Canal Filling Materials Following Retreatment Procedure. (PubMed, Eur Endod J) - "No system was capable of completely eliminating obturated materials. The XP-endo Retreat-ment system showed the lowest incidence of crack formation and propagation and proved to be the most effective in removing gutta-percha and sealer."

Clinical • Journal

Combining recombinant human endostatin with third-generation EGFR-TKIs in advanced EGFR-sensitive mutant non-small cell lung cancer. (PubMed, J Thorac Dis) - "The incidence of AEs of any level was higher in the E + T group than the T group (53.2% vs. 45.1%, P=0.39). In this real-world study, the combination of recombinant human endostatin and third-generation EGFR-TKIs significantly improved the ORR, PFS, and OS in previously untreated advanced EGFR-mutant NSCLC patients and thus represents a promising treatment option that requires further prospective evaluation."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • TP53

Long-term survival in advanced pulmonary large-cell neuroendocrine carcinoma after multi-line immunochemotherapy and anti-angiogenic therapy: a case report. (PubMed, Front Immunol) - "This report presents the case of a 45-year-old Chinese woman with advanced PLCNEC who received first-line treatment with a four-drug regimen consisting of etoposide, cisplatin, camrelizumab, and endostar...Second-line therapy with atezolizumab, bevacizumab, and docetaxel achieved a PFS2 of 1 year. Third-line treatment maintained atezolizumab and introduced the anti-angiogenic agent anlotinib and chemotherapeutic agent pemetrexed, resulting in a PFS3 of 6 months...This case illustrates the potential for long-term survival in advanced PLCNEC through intensive, multi-line combination therapies. The favorable outcome observed in this patient supports further investigation of such combination strategies in clinical studies."

Journal • Endocrine Cancer • Lung Cancer • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Single-Arm, Phase II Clinical Study of Chidamide Combined with Pemetrexed, Platinum-Based Chemotherapy, and Endostar as Second-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) with Extensive Progression After EGFR-TKI Resistance (ChiCTR) - P2 | N=59 | Recruiting | Sponsor: Fujian Provincial Hospital; Fujian Provincial Hospital

New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas (clinicaltrials.gov) - P2 | N=52 | Completed | Sponsor: Fudan University | Unknown status ➔ Completed | N=76 ➔ 52

Enrollment change • Trial completion • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

ECWHCCFLACC: Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma (clinicaltrials.gov) - P2 | N=120 | Completed | Sponsor: Yong Zhang,MD | Unknown status ➔ Completed | Phase classification: P3 ➔ P2

Phase classification • Trial completion • Cervical Cancer • Oncology • Solid Tumor

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer. (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Hua Zhang | Trial primary completion date: Aug 2025 ➔ Sep 2026

Trial primary completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Integrated Traditional Chinese and Western Medicine in Lung Adenocarcinoma with Rare EGFR Mutation and Nephrotic Syndrome: A Case Report. (PubMed, Cancer Manag Res) - "The scarcity of approved EGFR-TKIs targeting rare EGFR mutations in NSCLC, coupled with nephrotic syndrome-induced renal impairment, hypoalbuminemia, and massive pleural effusion refractory to conventional management, prompted the development of a personalized multimodal approach.A multimodal therapeutic regimen incorporating albumin-bound paclitaxel, intrathoracic perfusion of Endostar (recombinant human endostatin), and traditional Chinese medicine (TCM) was implemented, achieving effective disease control. Notably, the treatment resulted in significant tumor shrinkage (reduction rate: 48.1% by RECIST 1.1), complete resolution of malignant pleural effusion, and marked improvement in nephrotic syndrome parameters. The synergistic effects of targeted chemotherapy, anti-angiogenic therapy, and TCM-based symptom modulation highlight the potential of integrative approaches in managing advanced malignancies with complex molecular profiles and multisystem complications."

Journal • Glomerulonephritis • Lung Adenocarcinoma • Lung Cancer • Nephrology • Non Small Cell Lung Cancer • Oncology • Renal Disease • Respiratory Diseases • Solid Tumor • EGFR • TP53

Efficacy analysis of endostar combined with chemoradiotherapy and immune checkpoint inhibitors in locally advanced non-small cell lung cancer. (PubMed, Discov Oncol) - "Endostar combined with synchronous chemoradiotherapy followed by Endostar maintenance therapy can improve the survival of patients with locally advanced NSCLC who could not undergo surgery, without increasing adverse reactions, and has certain clinical guiding significance."

Checkpoint inhibition • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Patient With Advanced Aggressive B2 Thymoma Achieved Positive Outcomes Post CAP-Endostar Combination Therapy. (PubMed, Clin Respir J) - "After six cycles of chemotherapy and chest radiotherapy, the tumor size decreased from 72.43 to 24 mm, showing a significant improvement in patient efficacy. After a follow-up of 50 months, the patient remained well, without local recurrence or distal metastasis, and maintained a partial response (PR)."

Journal • Oncology • Solid Tumor • Thrombosis • Thymoma • Thymus Cancer

Efficacy and safety analysis of Endostar in cross-line therapy in patients with advanced non-small cell lung cancer (ChiCTR) - P=N/A | N=290 | Recruiting | Sponsor: The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university

New trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Real-word research on the effect and safety of gemcitabine combined with PD-1 inhibitors and recombinant human endostatin in refractory recurrent nasopharyngeal carcinoma. (ASCO 2025) - P2 | "Real-world data demonstrated that GEP was well-tolerated and effective in patients with refractory recurrent NPC. Radiotherapy, especially high-dose radiotherapy may contribute to ORR and PFS."

Clinical • Cardiovascular • Chronic Obstructive Pulmonary Disease • Constipation • Dermatology • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Hepatology • Immunology • Liver Failure • Nasopharyngeal Carcinoma • Oncology • Pruritus • Respiratory Diseases • Solid Tumor

Sintilimab + Nab-PP Combined with Recombinant Human Vascular Endothelial Inhibitor for Locally Advanced/Advanced and Recurrent Metastatic Squamous Non-Small Cell Lung Cancer: Study Protocol for a Single-Arm, Multi-Centre Phase II Clinical Study. (PubMed, Technol Cancer Res Treat) - "Patients will receive endostar (210 mg/dose, 72 h), sintilimab (200 mg/dose), and chemotherapy (nab-pp, carboplatin/cisplatin + albumin-bound paclitaxel) every 3 weeks for up to 6 cycles, followed by maintenance therapy until progression or intolerable toxicity. Radiological assessments will occur every 8 weeks initially, then every 12 weeks. Biomarker analysis and quality of life assessments will be performed."

Clinical protocol • IO biomarker • Journal • P2 data • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor